These medications have demonstrated significant weight loss (5-22%) and metabolic benefits in rigorous clinical trials when prescribed and monitored by healthcare providers
Energy expenditure research has documented increases in metabolic rate markers in pre-clinical models treated with Retatrutide, with studies attributing this in part to the glucagon receptor component
Here are eight takeaways from our conversation with Kessler about using the GLP-1 drugs, and the changing landscape of weight loss
Patients who remain on a stable maintenance dose frequently report ongoing improvements in portion control and reduced cravings
(2024) specifically investigated the impact of GLP-1 agonists on diabetic foot ulcers and related complications, including lower limb amputation, DFU-related hospitalizations, and mortality
If you have thyroid nodules, discuss the findings with your endocrinologist before proceeding